[Recombinant factor VIIa (rFVIIa). Description of use in a cohort of critical patients and prognostic markers].
OBJECTIVE
Describe and identify the factors associated with the survival of the patients who received treatment with rFVIIa in an Intensive Care Unit (ICU).


METHODS
Longitudinal, ambispective, observational, descriptive study in a series of clinical cases performed from July 20, 2004 to July 20, 2006.


METHODS
The study population included 16 hospitalized patients in the Intensive Medicine Department (ICU) of the Hospital Marqués de Valdecilla (Santander).


METHODS
Inclusion criteria were: Patients who required rFVIIa at some time of their stay in the ICU.


RESULTS
Hemodynamic improvement of the patients treated with rFVIIa in an ICU, within the first 3 hours of the infusion (evaluated by an increase of SBP > 20 mmHg and/or increase of DBP > 8 mmHg) was associated to greater survival.


CONCLUSIONS
The present series of cases, with the disadvantage of its heterogeneity and the limited number of patients, stresses the role of hemodynamic improvement as a differentiating factor between those patients who survive and those who do not.
González Castro
A
A
Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander. jandro120475@hotmail.com
Suberviola Cañas
B
B
Miñambres
E
E
Ortiz Melón
F
F
D000328:Adult; D015331:Cohort Studies; D016638:Critical Illness; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D015942:Factor VIIa